Clinical stage company Main asset: anticancer immunotherapy DNA. In Phase I/II human trials conducted ex-US, Elenagen demonstrated a statistically significant extension of progression-free (PFS) and overall (OS) survival for stage III/IV cancer patients. The primary goal is to repeat and extend the ex-US clinical trials as FDA/EMA phase II trials in the USA/EU and/or out-licensing. Repeating and extending a statistically significant success in the USA/EU is a low-risk, high-reward proposition.

Alternative markets:

- Human diseases of chronic inflammation

- Veterinary medicine